(Q37987352)

26 August 2017

title

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms (English)

1 reference

inflammatory bowel diseases

26 August 2017

main subject

0 references

0 references

0 references

0 references

1 reference

1 reference

1 reference

William Jeffery Sandborn

series ordinal

4

object named as

William J Sandborn

1 reference

26 August 2017

3

Brian G Feagan

1 reference

26 August 2017

1

Ingrid Ordás

1 reference

26 August 2017

2

Diane R Mould

1 reference

26 August 2017

language of work or name

English

0 references

publication date

22 February 2012

1 reference

Clinical Pharmacology & Therapeutics

26 August 2017

published in

1 reference

26 August 2017

volume

91

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

635-646

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Antibody Structure and Molecular Immunology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Unravelling the pathogenesis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Clinical pharmacokinetics and use of infliximab

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Clinical pharmacokinetics of TNF antagonists: how do they differ?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Monoclonal antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

A Theoretical Model of γ-Globulin Catabolism

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Metabolic properties of IgG subclasses in man

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

1 reference

7 January 2021

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Elimination mechanisms of therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Is intent-to-treat analysis always (ever) enough?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Body mass index and clinical response to infliximab in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.328

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.328

1 reference

26 August 2017

1 reference